Umbilical cord blood transplantation with HSC835
Phase 1/2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inherited Metabolic Disorders IMD
Conditions
Inherited Metabolic Disorders IMD
Trial Timeline
Oct 10, 2017 → May 18, 2020
NCT ID
NCT02715505About Umbilical cord blood transplantation with HSC835
Umbilical cord blood transplantation with HSC835 is a phase 1/2 stage product being developed by Novartis for Inherited Metabolic Disorders IMD. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02715505. Target conditions include Inherited Metabolic Disorders IMD.
What happened to similar drugs?
0 of 1 similar drugs in Inherited Metabolic Disorders IMD were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02715505 | Phase 1/2 | Withdrawn |
Competing Products
4 competing products in Inherited Metabolic Disorders IMD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Cysteamine Bitartrate | Amgen | Phase 2 | 35 |
| PF-05089771 + Placebo | Pfizer | Phase 2 | 35 |
| BIIB074 + Placebo | Biogen | Phase 2 | 32 |
| Vatiquinone | PTC Therapeutics | Phase 3 | 37 |